His primary areas of study are Alzheimer's disease, Pittsburgh compound B, Pathology, Amyloid and Internal medicine. His Alzheimer's disease research includes themes of Central nervous system disease, Posterior cingulate, Asymptomatic, Dementia and Precuneus. His Pittsburgh compound B research integrates issues from Florbetaben, Positron emission tomography, Nuclear medicine, Magnetic resonance imaging and Cognitive disorder.
His Amyloid study combines topics from a wide range of disciplines, such as Genetically modified mouse, Imaging agent, In vivo and Biochemistry. His studies in Internal medicine integrate themes in fields like Endocrinology, Neuroscience, Brain mapping and Oncology. His research investigates the link between Alzheimer's disease biomarkers and topics such as White matter that cross with problems in Cortex.
His main research concerns Pathology, Amyloid, Internal medicine, Pittsburgh compound B and Positron emission tomography. His biological study spans a wide range of topics, including Preclinical imaging and In vivo. In general Amyloid study, his work on Cerebral amyloid angiopathy often relates to the realm of Congo red, thereby connecting several areas of interest.
Chester A. Mathis usually deals with Internal medicine and limits it to topics linked to Endocrinology and Serotonin and 5-HT receptor. His Pittsburgh compound B research incorporates elements of Fluorodeoxyglucose, Down syndrome, Apolipoprotein E and Precuneus. His Alzheimer's disease research is multidisciplinary, relying on both Central nervous system disease, Neuroscience, Degenerative disease, Dementia and Atrophy.
His scientific interests lie mostly in Internal medicine, Pittsburgh compound B, Endocrinology, Amyloid and Down syndrome. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Hyperintensity. The concepts of his Pittsburgh compound B study are interwoven with issues in Positron emission tomography and Precuneus.
His Endocrinology research is multidisciplinary, incorporating perspectives in Receptor, Antagonist and Psychosis. His Amyloid research is multidisciplinary, incorporating elements of Biomedical engineering, Apolipoprotein E, Neuroscience and Cohort. In general Pathology, his work in Senile plaques, Amyloidosis and Histology is often linked to Fluorescence microscope linking many areas of study.
Chester A. Mathis focuses on Pittsburgh compound B, Internal medicine, Pathology, Alzheimer's disease and Dementia. The subject of his Pittsburgh compound B research is within the realm of Amyloid. His Internal medicine research incorporates themes from Major depressive disorder and Endocrinology.
The Pathology study combines topics in areas such as White matter, Entorhinal cortex and Basal ganglia. His studies deal with areas such as Trail Making Test and Cognition, Neuroscience as well as Alzheimer's disease. The various areas that Chester A. Mathis examines in his Dementia study include Biomarker, Gait, Preferred walking speed and Gerontology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E. Klunk;Henry Engler;Agneta Nordberg;Yanming Wang.
Annals of Neurology (2004)
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory
Randy L. Buckner;Abraham Z. Snyder;Benjamin J. Shannon;Gina LaRossa.
The Journal of Neuroscience (2005)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
Anne M. Fagan;Mark A. Mintun;Robert H. Mach;Sang-Yoon Lee.
Annals of Neurology (2006)
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.
M. A. Mintun;G. N. LaRossa;Y. I. Sheline;C. S. Dence.
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Howard Jay Aizenstein;Robert D. Nebes;Judith A. Saxton;Julie C. Price.
JAMA Neurology (2008)
SYNTHESIS AND EVALUATION OF 11C-LABELED 6-SUBSTITUTED 2-ARYLBENZOTHIAZOLES AS AMYLOID IMAGING AGENTS
Chester A. Mathis;Yanming Wang;Daniel P. Holt;Guo Feng Huang.
Journal of Medicinal Chemistry (2003)
Post-mortem Correlates of in Vivo PiB-PET Amyloid Imaging in a Typical Case of Alzheimer's Disease
Milos D. Ikonomovic;William E. Klunk;Eric E. Abrahamson;Chester A. Mathis.
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
Clifford R. Jack;Val J. Lowe;Matthew L. Senjem;Stephen D. Weigand.
C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O Rinne;David J Brooks;Martin N Rossor;Nick C Fox.
Lancet Neurology (2010)
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.
Kerryn Elizabeth Pike;Gregory Raymond Savage;Victor L Villemagne;Steven Ng.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: